30m for Evotec cancer spin-out
German biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses.
Partnership in pursuit of new antibiotics class
A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel antibiotics class.
Drug puts CAR T activity on hold
German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact.
License deal in oncolytic virotherapies
Oncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer therapies.
Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal
Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.
Smart bra set to detect breast cancer
A French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography.
GARDP wants five AMR breakers by 2025
GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.
Sanifit raise 72.2m to push SNF472 development
Sanifit has bagged 72.2m in Spains largest private biotech fundraise.
Genfit in $228m deal with Terns Pharmaceuticals
Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.
Vesalius Biocapital III Fund closes at 120 million
Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at 120m.